Soleus Capital Management L.P. Has $31.95 Million Stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Soleus Capital Management L.P. grew its position in Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 11.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,494,420 shares of the company’s stock after acquiring an additional 150,755 shares during the period. Jasper Therapeutics accounts for 2.0% of Soleus Capital Management L.P.’s portfolio, making the stock its 16th largest holding. Soleus Capital Management L.P. owned about 9.96% of Jasper Therapeutics worth $31,951,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of JSPR. Braidwell LP increased its holdings in Jasper Therapeutics by 47.9% during the 4th quarter. Braidwell LP now owns 714,658 shares of the company’s stock valued at $15,279,000 after purchasing an additional 231,358 shares in the last quarter. Integral Health Asset Management LLC grew its holdings in shares of Jasper Therapeutics by 85.7% during the fourth quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company’s stock worth $13,897,000 after purchasing an additional 300,000 shares during the last quarter. Rock Springs Capital Management LP grew its holdings in shares of Jasper Therapeutics by 0.9% during the fourth quarter. Rock Springs Capital Management LP now owns 463,088 shares of the company’s stock worth $9,901,000 after purchasing an additional 4,000 shares during the last quarter. Boxer Capital Management LLC acquired a new stake in shares of Jasper Therapeutics in the fourth quarter valued at $7,483,000. Finally, Russell Investments Group Ltd. raised its holdings in shares of Jasper Therapeutics by 16.9% in the fourth quarter. Russell Investments Group Ltd. now owns 247,272 shares of the company’s stock valued at $5,287,000 after buying an additional 35,746 shares during the last quarter. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Trading Up 1.2%

Shares of NASDAQ:JSPR opened at $4.93 on Monday. Jasper Therapeutics, Inc. has a 1-year low of $3.13 and a 1-year high of $26.84. The stock has a market capitalization of $74.06 million, a P/E ratio of -1.04 and a beta of 2.74. The business has a 50-day moving average price of $4.60 and a two-hundred day moving average price of $10.86.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings results on Monday, May 12th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.24). As a group, equities analysts predict that Jasper Therapeutics, Inc. will post -4.47 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on JSPR. Oppenheimer decreased their price objective on shares of Jasper Therapeutics from $80.00 to $65.00 and set an “outperform” rating on the stock in a report on Thursday. UBS Group reduced their target price on shares of Jasper Therapeutics from $38.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, May 13th. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Jasper Therapeutics in a research note on Tuesday, March 11th. Ten research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Jasper Therapeutics presently has an average rating of “Buy” and an average target price of $62.22.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.